anasrequiredbasis.
andChakravarthy [2] studies,bothshowedsimilarefficacywhengivenona4 weeklyregimenoronasrequiredbasis.Therewerestudies lookingateitherranibizumaborbevacizumabstartingwith loadingdoseregimefollowedby4-weeklyasrequired retreatmentwithencouragingresults [3] [4] . Asalargermolecule,bevacizumabhasbeenshownto penetratetheprimateretinapoorlyandthereforehasalonger half-lifeintheeye [5] .Thelattermeasuredbyaqueous samplinginnon-vitrectomisedhumaneyeswas9.8d [6] .The samegroupreportedranibizumabhalf-lifeof7.2dusingthe exacttechnique [7] .Thesemeasurementswerenottakenfrom theposteriorsegment,howevernumerousanimalmodels haveshownthataqueousandvitreoussamplestohavevery similarvalues [8] [9] [10] . Studieshaveshowedbevacizumabeffectcanlastupto6to 8wk [11] [12] [13] butnot12wk [14] .Tufail [15] hadevaluatedthe efficacyofbevacizumabwith3loadingdosesfollowedby furthertreatmentifindicatedona6weeklyintervaland showedameangainof7.0lettersatoneyear.Inour institution,weemployedbevacizumabinasimilarfashionfor afewyearspriortochangingitto4-weeklyafterthe publicationofCATT [1] andChakravarthy [2] . where ofthe65patientsinthebevacizumabgroup,32%gained15 ormoreletters,meanvisualacuityincreasedby7.0letters withamedianof7injections. Intheranibizumabgroup,ourmeanvisualacuitygainedwas 9.2letters,centralfovealthicknesswasreducedby160 滋m, 36%gainedmorethan15letterswith10.3injectionsover 24mo.PrONTOstudy [3] showedaslightlybetteroutcome wheretheirmeangainofletterswas11.1,had212 滋m reductionofCMT,43%gainedmorethan15letterswith9.9 injectionsoversameperiodoftime.Thiscouldbeduetoa higherbaselineacuityinPrONTOcomparedtoours. Inourstudy,weadoptedthetreatmentregimenemployedin PrONTO [3] fortheranibizumabgroupandABCtrial [15] forthe bevacizumabgroupwherepatientsreceivedthreeloading dosefollowedbyprorenats(prn)4or6weeklytreatment. Theuseofloadingdosehasshownbetteroutcomethanno loadingdose [18] [19] .Therationalethatbevacizumabresides longerinthevitreouscavitysinceitisalargermoleculethan ranibizumab;andphaseIstudyonbevacizumabhas demonstratedthatasingleinjectioncould achievea therapeuticeffectlastingsixupto8wk [11] [12] butnotsustained ifgivenlongerthan12wk [14] .Thisapproachwouldmakethe useofbevacizumablessresourceintensiveandreduce burdenoffrequentfollowupvisits. Followingtherecentapprovalofafliberceptfromthe NationalInstituteforHealthandCareExcellence(NICE)in theUnitedKingdom,wehavefundingprovidedfortheuseof bothafliberceptandranibizumabasthetreatmentofchoice forneovascularAMDandhence,theuseofbevacizumabhas beenreducedsignificantlyinourinstitution.Nonetheless, bevacizumabhasaplaceinahealthcaresystemthathavea limitedresourcesespeciallyithasbeenshowntobe non-inferiortoranibizumab [1] [2] .The6weeklyregimenfor bevacizumabcanbeconsideredforthosepatientswhocannot attend4weeklyappointmentsoraffordotherlicenced alternatives. Therehavebeendifferenttreatmentprotocolsdevelopedas individualisedtherapy.Treat-and-extendprotocolhas becomeincreasinglypopularwiththegoalofkeepingthe maculardrybycontrollingthetreatmentintervalwhichcan begraduallyextendedtoamaximumintervalof12wk.Inthe LUCAStrial [20] ( =432),theimprovementinvisualacuity were8.2and8.0,andthemeannumberofinjectionwas8.0 and8.8forbothranibizumabandbevacizumabrespectively atyear1.Itisinterestingtonotethattheseresultsare comparabletothatofoursinvisualacuitygaininboth treatmentgroupsbutattheexpensesof2moreinjections neededcomparedtoourstudy.Nonetheless,itshowed equivalenteffectsonvisualacuitygaininbothranibizumab andbevacizumab. Ourstudydidnotlookattherateofadverseeffects,asitwas notpoweredtoexaminethesafetyprofileforthetwodrugs. Therewashowevernodocumentedocularorsystemic adverseeffectovertheuseofeitheragents. Thisstudyhadafewlimitations.Itwasaretrospectiveand non-randomisedtrial.Aprospectivestudy,withanadditional armofbevacizumabat4weeklymayprovidemoreuseful informationintowhether6weeklyregimenisnon-inferiorto thecurrentrecommendedtreatment.However,wedonot haveadequatenumberofpatientsforthis. Inconclusion,wecouldnotdemonstratethatbevacizumab 6-weeklyprnwasnon-inferiortoranibizumab4-weeklyprn intermsofBCVAgained.Despitethe6-weeklyinterval, bevacizumabrequiredonemoreinjectioncomparedto ranibizumabattheendofyear2.
